business

Eli Lilly Acquires Three Vaccine Developers for Up to $3.8 Billion

26 Mayıs 2026Bloomberg

Eli Lilly & Co. is making a significant move into the vaccine sector by acquiring three clinical-stage vaccine developers for up to $3.8 billion.
This strategic investment aims to position the company as a leader in the field of infectious diseases. The funding for this expansion is being sourced from the profits generated by Lilly's obesity treatments.
The vaccine market has seen heightened interest and investment following the global health crisis caused by the pandemic. Companies are increasingly recognizing the importance of being involved in infectious disease prevention, which has led to a surge in mergers and acquisitions within the sector.
Eli Lilly's foray into the vaccine market highlights a broader trend among pharmaceutical companies to diversify their portfolios, especially in the wake of the COVID-19 pandemic. By leveraging its financial gains from obesity drugs, Lilly is not only addressing a critical public health need but also positioning its…

NewsAI özeti

This summary is based on information from Bloomberg and is intended for informational purposes only.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.